News
-
February 14, 2020
Palleon’s first CSO explains how they (and she) got here; Enterprise taps Roche and Novartis vet David Morris as CMO
Endpoints
-
February 10, 2020
Beyond PROTACs and the proteasome: broadening the TAC toolbox
BioCentury
-
January 31, 2020
Carolyn Bertozzi’s glycorevolution
Chemical & Engineering News
-
January 06, 2020
SIGLECs go from homing beacons to next-generation checkpoints
BioCentury
-
July 20, 2019
Glycoscience fuels a new breed of cancer immunotherapy
Chemical & Engineering News
-
April 09, 2019
Carolyn Bertozzi on becoming a chemical biologist/glycobiologist
The Long Run with Luke Timmerman
-
February 11, 2019
Palleon: Sweeter checkpoints
BioCentury
-
November 28, 2018
The Biology of Sugars Points to a Sweet Strategy for Treating Cancer
Scientific American
-
October 04, 2017
Startup Palleon has a sweet plan for cancer immunotherapy
FierceBiotech
-
March 21, 2017
Cancer cells cast a sweet spell on the immune system
ScienceNews
